ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer - PubMed (original) (raw)
Comparative Study
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
Jérôme Viguier et al. Clin Cancer Res. 2005.
Abstract
Purpose: The aim of our study was to assess whether the polymorphism of the nucleotide excision repair enzyme, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), had an effect on the tumor response in patients treated with standard chemotherapy regimens for a metastatic colorectal cancer. We have studied the synonymous polymorphism that causes a single nucleotide change C to T at codon 118 converting a codon of common usage (AAC) to a less used codon (AAT), both coding asparagine. This change results in a decreased ERCC1 gene expression, which impairs repair activity.
Experimental design: Ninety-one patients with a median age of 55.1 years treated for a metastatic colorectal cancer were included in our retrospective study. The ERCC1 polymorphism was analyzed in the normal tissue of all patients.
Results: Twenty (22%) were homozygous for AAC codon (C/C genotype), 30 were (33%) homozygous for AAT codon (T/T genotype), and 41 (45%) were heterozygous (C/T genotype). The objective response rate to oxaliplatin in combination with 5-fluorouracil (5-FU) was significantly higher in the T/T genotype group compared with the C/T and the C/C genotype groups (61.9%, 42.3%, and 21.4%, respectively; P = 0.018). By contrast, no significant difference was observed when patients were treated with either 5-FU alone (45%, 29.2%, and 33.3%, respectively; P = 0.407) or in combination with irinotecan (46.1%, 25.0%, and 27.3%, respectively; P = 0.305).
Conclusions: Our observations allowed us to define the first useful predictive criterion for oxaliplatin/5-FU response in patients with metastatic colorectal cancer.
Comment in
- ERCC1 and clinical resistance to platinum-based therapy.
Reed E. Reed E. Clin Cancer Res. 2005 Sep 1;11(17):6100-2. doi: 10.1158/1078-0432.CCR-05-1083. Clin Cancer Res. 2005. PMID: 16144907 No abstract available. - Genetic effect of ERCC1 codon 118 polymorphism and confounding factors.
Ryu JS, Viguier J, Praz F. Ryu JS, et al. Clin Cancer Res. 2006 Aug 1;12(15):4784; author reply 4784-5. doi: 10.1158/1078-0432.CCR-06-0419. Clin Cancer Res. 2006. PMID: 16899630 No abstract available.
Similar articles
- The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW. Liang J, et al. Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4. Cancer Chemother Pharmacol. 2010. PMID: 19960344 - ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. Park DJ, et al. Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6. Clin Adv Hematol Oncol. 2003. PMID: 16224397 - Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ. Kim SH, et al. Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e. Am J Clin Oncol. 2009. PMID: 19194123 - A review of excision repair cross-complementation group 1 in colorectal cancer.
Bohanes P, Labonte MJ, Lenz HJ. Bohanes P, et al. Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28. Clin Colorectal Cancer. 2011. PMID: 21855036 Review. - Biological and predictive role of ERCC1 polymorphisms in cancer.
Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M. Formica V, et al. Crit Rev Oncol Hematol. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28. Crit Rev Oncol Hematol. 2017. PMID: 28259288 Review.
Cited by
- ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.
Kim CY, Seo SH, An MS, Kim KH, Bae KB, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH. Kim CY, et al. Ann Coloproctol. 2015 Jun;31(3):92-7. doi: 10.3393/ac.2015.31.3.92. Epub 2015 Jun 30. Ann Coloproctol. 2015. PMID: 26161376 Free PMC article. - A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.
Hansen RD, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou-Nielsen O, Vogel U. Hansen RD, et al. BMC Cancer. 2008 Feb 20;8:54. doi: 10.1186/1471-2407-8-54. BMC Cancer. 2008. PMID: 18289367 Free PMC article. - GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK, Yeh CT. Lin WR, et al. Medicine (Baltimore). 2016 Apr;95(17):e3487. doi: 10.1097/MD.0000000000003487. Medicine (Baltimore). 2016. PMID: 27124048 Free PMC article. - Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC. Gandara DR, et al. J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470925 Free PMC article. - Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome.
Huang MY, Wang JY, Huang ML, Chang HJ, Lin SR. Huang MY, et al. Int J Mol Sci. 2013 Feb 19;14(2):4121-34. doi: 10.3390/ijms14024121. Int J Mol Sci. 2013. PMID: 23429196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous